PCSK9 inhibitor,Evolocumab is highly efficient in patients with elevated cholesterol or stations, hetero zygous familial hypercholesterolemia(HeFH), homo zygous familial hyper-cholesterolemia (HoFH),a genetic disorder.
Amgen,the developer of the Evolocumab has filed for US FDA approval .The data filed contains information from ten phase 3 clinical trials performed on 6,800 patients , including more than 4500 patients with high cholesterol.
PCSK9 , is a protein that reduces the Liver ability to remove harmful cholesterol from the blood.
Amgen (AMGN) is an American bio pharmaceutical company headquarters in Thousand Oaks , California.
Amgen,the developer of the Evolocumab has filed for US FDA approval .The data filed contains information from ten phase 3 clinical trials performed on 6,800 patients , including more than 4500 patients with high cholesterol.
PCSK9 , is a protein that reduces the Liver ability to remove harmful cholesterol from the blood.
Amgen (AMGN) is an American bio pharmaceutical company headquarters in Thousand Oaks , California.